Benefits
Blood pressure reduction in hypertensive adults
Clinical trials in adults with mild hypertension show modest but consistent reductions in systolic and diastolic blood pressure with ABG10+® supplementation over weeks to months of use. Effect sizes smaller than first-line antihypertensives but useful as adjunct.
Total and LDL cholesterol reduction
Clinical trials show meaningful reductions in total cholesterol and LDL cholesterol with aged black garlic supplementation. Effects build over 12 weeks; combined with diet, produces additive lipid improvements.
S-allyl cysteine bioavailability advantage
Aging fresh garlic converts unstable allicin into stable, water-soluble S-allyl cysteine (SAC). SAC is much more bioavailable than allicin and provides reproducible plasma levels — a key advantage over raw garlic or basic powders.
Platelet aggregation modulation
Aged black garlic modestly inhibits platelet aggregation, supporting cardiovascular health. Effect is smaller than aspirin and clinically relevant primarily as general cardiovascular support, not as antiplatelet therapy.
Antioxidant capacity enhancement
Aged black garlic has significantly higher antioxidant capacity than raw garlic — the aging process concentrates polyphenols and Maillard reaction products with strong antioxidant activity.
Glycemic control support
Emerging evidence suggests aged black garlic supports glycemic control in metabolic syndrome and type 2 diabetes. Less robust than the cardiovascular evidence but consistent across small trials.
Odorless and well-tolerated
Unlike raw garlic supplements, aged black garlic produces no garlic breath or odor and rarely causes GI upset. Practical advantage that supports long-term adherence for cardiovascular and metabolic applications.
Mechanism of action
ACE inhibition (angiotensin-converting enzyme)
ABG10+® decreases ACE activity — same mechanism as prescription ACE inhibitors (lisinopril, captopril, ramipril). Mechanism for blood pressure reduction even in patients on prescription antihypertensive therapy.
Nitric oxide production enhancement
Increases endothelial nitric oxide synthase activity — enhanced NO production providing vasodilation and antioxidant effects. Mechanism for BP improvement and broader cardiovascular benefits.
S-allyl-L-cysteine (SAC) bioactive accumulation
Aging process accumulates SAC — water-soluble organosulfur compound with cardiovascular, antimicrobial, immunomodulatory, hepatoprotective, antidiabetic, anti-obesity, neuroprotective, renal protective properties (per in vitro and in vivo evidence). Mechanism for multi-system benefits.
Melanoidins (Maillard reaction antioxidants)
Aging produces melanoidins — Maillard reaction products with antioxidant activity. Distinct from typical phenolic antioxidants. Mechanism contributing to overall antioxidant capacity demonstrated in clinical trials.
Antioxidant capacity enhancement
Combined SAC + polyphenols + flavonoids + melanoidins provide comprehensive antioxidant profile. Direct ROS scavenging + endogenous antioxidant enzyme system support. Mechanism for cardiovascular and metabolic benefits.
Xanthine oxidase modulation
ABG10+® reduces blood uric acid levels — mechanism likely involves xanthine oxidase modulation. Hyperuricemia is independent CV risk factor; reduction is added benefit.
Lipoprotein subclass remodeling
NMR studies show ABG10+® induces qualitative lipoprotein improvements: large HDL particles increase phospholipid + decrease triglyceride content; XXL-VLDL particles reduce cholesterol content. Mechanism beyond traditional 'lower LDL/raise HDL' framework — addresses lipoprotein quality relevant to atherogenic risk.
Clinical trials
Randomized triple-blind placebo-controlled trial (Tomas-Sanchez C, Solà R, Valls RM et al. 2023, Nutrients 15(17):3691, NCT04915053, doi:10.3390/nu15173691).
81 volunteers with Grade I hypertension already on prescribed antihypertensive drug treatment with persistent uncontrolled BP. Average 15-year hypertension history. Hospital Universitari Arnau de Vilanova (Lleida, Spain) and Atherothrombotic Disease Detection and Treatment Unit. 2-week placebo run-in phase + experimental phase. ABG10+® 250 mg/day vs placebo.
Additional 1.8 mmHg systolic + 1.5 mmHg diastolic BP reduction vs placebo in patients already ON prescription antihypertensive therapy — clinically meaningful adjunct evidence. Mechanism: enhanced NO release, increased antioxidant capacity, decreased ACE activity, lower blood uric acid. Foundational pivotal trial demonstrating real-world clinical utility as add-on therapy.
Randomized crossover double-blind sustained controlled trial (Sasaki K, Pedret A, Valls RM, Solà R et al. 2022, Nutrients 14(3):405, doi:10.3390/nu14030405).
67 hypercholesterolemic individuals with LDL-C ≥115 mg/dL. ABG10+® extract daily intake combined with dietary recommendations vs placebo. Crossover design.
Significant reductions in cardiovascular disease risk factors: 5.85 mmHg diastolic BP reduction vs placebo. Improvements in inflammatory, oxidative, and vasodilatory biomarkers. Foundational positive cardiovascular trial. Crossover methodology strengthens within-subject comparison.
Randomized triple-blind placebo-controlled trial (medRxiv 2026 preprint, doi:10.64898/2026.04.20.26351262v1).
75 Grade I hypertensive participants. 250 mg ABG10+® or placebo daily for 12 weeks. NMR spectroscopy lipoprotein subclass and composition analysis. K-means and PLS-DA metabolic clustering.
Significant reduction in total particles and HDL particles. XXL-VLDL particles: significant decrease in free + esterified cholesterol percentage with triglyceride percentage increase. Large HDL particles: beneficial remodeling (increased phospholipid, decreased triglyceride). Cluster analysis: participants with adverse baseline metabolic profile experienced greatest triglyceride and VLDL-lipid reductions. Qualitative lipoprotein improvements beyond standard panel — clinically novel evidence.